LNK754 is a farnesyltransferase inhibitor, used for the treatment of cancer and Alzheimer's disease.
LNK-754 (0.9 mg/kg) significantly reduces α-synuclein plaques in a mouse model of PD, APP(SL), at 6 months of age for 3 months[1].
[1]. Keith T Gagnon. HD Therapeutics-CHDI Fifth Annual Conference. IDrugs. 2010 Apr;13(4):219-23.
















